Antidiarrheal Drugs: Oral Rehydration, Loperamide, Bismuth and Infectious Diarrhea Safety

Medical education review — 10 November 2026. Not a substitute for individualized diagnosis, prescribing advice or local guidance.

Overview

Acute diarrhea is usually self-limited, but dehydration, inflammatory diarrhea and systemic illness require timely assessment. Antidiarrheal drugs may relieve selected symptoms; they never replace fluid and electrolyte replacement or evaluation for severe disease [1, 2, 3].

Initial assessment and red flags

Assess stool frequency, dehydration, urine output, fever, blood or mucus, abdominal tenderness, recent antibiotics, immune suppression and travel exposure. Severe dehydration, shock, altered mental status, severe pain or bloody diarrhea warrant urgent medical evaluation and targeted testing. Stool studies are especially relevant when fever, blood, severe cramps or sepsis is present [2].

First-line rehydration and nutrition

Reduced-osmolarity oral rehydration solution (ORS) is first-line for mild-to-moderate dehydration at any age. Sodium-glucose cotransport remains functional during most diarrheal illnesses and facilitates water absorption. Severe dehydration or shock warrants appropriate intravenous isotonic fluid replacement. Continue breastfeeding and resume age-appropriate food after initial rehydration; children may benefit from zinc in specified WHO programs [2, 3].

Classes and mechanisms

  • Loperamide: peripheral μ-opioid receptor agonist reduces intestinal propulsive motility; useful for selected immunocompetent adults with acute watery diarrhea, but not a replacement for fluids.
  • Diphenoxylate/atropine: opioid-related antimotility combination with systemic adverse-effect potential.
  • Bismuth subsalicylate: antisecretory and mild antimicrobial effects; avoid in people with salicylate allergy and use caution in children/teens with viral illness.
  • Racecadotril: enkephalinase inhibitor reduces intestinal secretion, available in some countries.
  • Bile acid sequestrants: cholestyramine or colesevelam can treat confirmed/suspected bile acid diarrhea in selected chronic cases; they are not general ‘toxin adsorbents.’
  • Rifaximin and other antibiotics: have restricted indications for selected bacterial syndromes, not routine management of uncomplicated watery diarrhea.

Avoiding harmful treatment

IDSA advises against loperamide in children younger than 18 years with acute diarrhea and against antimotility use when fever or inflammatory/bloody diarrhea raises concern for toxic megacolon. Avoid routine empiric antibiotics for most acute watery diarrhea without recent international travel; antibiotics can be harmful for certain Shiga toxin-producing E. coli infections because of hemolytic uremic syndrome risk [2]. Excessive loperamide dosing can cause serious ventricular arrhythmias [1].

Drug selection and product safety

Diphenoxylate also slows transit. Each US Lomotil tablet contains 2.5 mg diphenoxylate hydrochloride and 0.025 mg atropine sulfate. The small atropine component discourages deliberate overdosage. An overdose can still cause delayed respiratory depression and anticholinergic toxicity. The product is contraindicated in diarrhoea associated with invasive organisms or antibiotic-associated pseudomembranous colitis. [4]

Mild travellers’ diarrhoea usually resolves with supportive care. For severe travellers’ diarrhoea, including dysentery, CDC guidance favours azithromycin. Rifaximin is limited to noninvasive illness. These travel recommendations require clinical context. In a patient with bloody diarrhoea and suspected Shiga toxin-producing E. coli, obtain appropriate testing and avoid antibiotics when Shiga toxin 2 is present or the toxin genotype is unknown, owing to concern about haemolytic uraemic syndrome. [5, 2]

Persistent diarrhea and stewardship

Symptoms lasting over two weeks prompt consideration of parasites, medication effects, inflammatory bowel disease, malabsorption and functional disorders, alongside appropriately chosen stool testing. Persistent diarrhea should not automatically be treated with repeated antibiotic courses. Drug choice should follow etiology, severity and local resistance patterns [2, 3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Infectious Diseases Society of America. 2017 clinical practice guidelines for diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65:e45–e80. Available from: https://www.idsociety.org/practice-guideline/infectious-diarrhea
  3. World Health Organization. Diarrhoeal disease. Fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease
  4. Pfizer. Lomotil (diphenoxylate hydrochloride and atropine sulfate tablets). DailyMed prescribing information. [cited 2026 Nov 10]. View source.
  5. Centers for Disease Control and Prevention. Travelers’ diarrhea. In: CDC Yellow Book 2026. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *